A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab
(CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.